Biocartis Announces Exercise Of The Over-Allotment Option In Full Bringing The Gross Proceeds Of Its Initial Public Offering To Eur115 Million
Mechelen, Belgium, 19 May 2015 – Biocartis Group NV (the “Company” or “Biocartis”), an innovative molecular diagnostics company, today announces that the over-allotment option granted in connection with its initial public offering (the "Offering") has been exercised in full, thereby bringing the gross proceeds of the Offering to EUR 115 million in total.
The Company initially issued 8,695,652 new shares in the Offering at an offer price of EUR 11.50 per share. The Company had also granted to KBC Securities NV/SA, acting as stabilisation manager, on behalf of KBC Securities NV/SA, Kempen & Co N.V. and Petercam NV/SA (the "Underwriters"), an over-allotment option to subscribe for up to 1,304,347 additional new shares at a price of EUR 11.50 per share to cover over-allotments or short positions, if any, in connection with the Offering.
KBC Securities NV/SA, acting as stabilisation manager, on behalf of the Underwriters, has exercised the over-allotment option in full, so that the Company raised an additional EUR 15.0 million in gross proceeds and issued 1,304,347 additional new shares. Following the exercise of the over-allotment option, the Company has 40,448,360 outstanding shares. For an overview of the dilution resulting from the Offering, see the section "Principal Shareholders" of the prospectus (the "Prospectus") that has been prepared by the Company in connection with the Offering and that is available on the Company's website (www.biocartis.com).
As a result of the exercise of the over-allotment option the stabilisation period following the Offering has ended prior to the expiry of the maximum term of 30 days as of the date of the first listing of the Company's shares. In accordance with article 9(3) of EU Regulation No 2273/2003 and article 5, §2 of the Belgian Royal Decree of 17 May 2007, KBC Securities NV/SA, as stabilisation manager, indicated that no stabilisation has taken place.
For more information, please contact:
Biocartis
Rudi Pauwels, CEO/Hilde Windels, CFO
+32 15 632 600
press@biocartis.com
Consilium Strategic Communications
Amber Bielecka/Jessica Hodgson/Chris Welsh/Laura Thornton
+44 (0) 203 709 5701 (London, UK)
biocartis@consilium-comms.com
About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.
Biocartis launched the Idylla™ platform commercially in September 2014 together with its first assay to identify BRAF mutations in metastatic melanoma. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide.
Further information can be found at: www.biocartis.com
Help employers find you! Check out all the jobs and post your resume.
KBC Securities NV/SA, acting as stabilisation manager, on behalf of the Underwriters, has exercised the over-allotment option in full, so that the Company raised an additional EUR 15.0 million in gross proceeds and issued 1,304,347 additional new shares. Following the exercise of the over-allotment option, the Company has 40,448,360 outstanding shares. For an overview of the dilution resulting from the Offering, see the section "Principal Shareholders" of the prospectus (the "Prospectus") that has been prepared by the Company in connection with the Offering and that is available on the Company's website (www.biocartis.com).
As a result of the exercise of the over-allotment option the stabilisation period following the Offering has ended prior to the expiry of the maximum term of 30 days as of the date of the first listing of the Company's shares. In accordance with article 9(3) of EU Regulation No 2273/2003 and article 5, §2 of the Belgian Royal Decree of 17 May 2007, KBC Securities NV/SA, as stabilisation manager, indicated that no stabilisation has taken place.
For more information, please contact:
Biocartis
Rudi Pauwels, CEO/Hilde Windels, CFO
+32 15 632 600
press@biocartis.com
Consilium Strategic Communications
Amber Bielecka/Jessica Hodgson/Chris Welsh/Laura Thornton
+44 (0) 203 709 5701 (London, UK)
biocartis@consilium-comms.com
About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.
Biocartis launched the Idylla™ platform commercially in September 2014 together with its first assay to identify BRAF mutations in metastatic melanoma. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide.
Further information can be found at: www.biocartis.com
Help employers find you! Check out all the jobs and post your resume.